Morgantown, WVNCT04875702Now EnrollingIRB Ready

Gout Clinical Trial in Morgantown, WV

Access cutting-edge gout treatment through this phase 4 clinical trial at a research site in Morgantown. Study-provided care at no cost to qualified participants.

Sponsored by Massachusetts General Hospital

Quick Self-Assessment

See if you qualify for this Morgantown location

Preparing your pre-screening questions…

Expert Care in Morgantown

Access gout specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related gout treatment provided free

Apply for This Morgantown Location

Check if you qualify for this gout clinical trial in Morgantown, WV

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Morgantown

    Convenient for WV residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Morgantown site if eligible
  4. 4Begin participation

About This Gout Study in Morgantown

The TRUST study is a randomized, controlled multicenter study to evaluate the management of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine the most beneficial for a patient-centered gout outcomes, as well as relevant cardiovascular-metabolic-renal endpoints.

Sponsor: Massachusetts General Hospital

Who Can Participate

Inclusion Criteria

To be eligible to be enrolled in the study, each patient must:
Provide signed written or electronic informed consent.
Be between 18 and 90 years old.
Be in a participating primary care practice with at least one visit in the previous 36 months.
Be diagnosed with gout by the 2015 ACR/EULAR criteria, with 8 or more points on the 2015 ACR/EULAR criteria scoring algorithm.
Have experienced at least one gout flare attributed in the previous 12 months.
Have a baseline inter-critical serum urate (SU) ≥ 6.0 mg/dL (at screening or in the 30 days before screening)
Be able to swallow pills.
Agree to practice effective measures of birth control if of reproductive potential. Exclusion Criteria Candidates who meet any of the following criteria will be excluded from the study:
Diagnosis of CKD Stage 3B or worse (eGFR \< 45 mL/min/ 1.73 m2) at screening
More than one subcutaneous tophus on clinical examination at screening
Two or more episodes of renal colic in the past 5 years
Unable to provide informed consent.
AST/ALT \> 3 Ă— upper limit of normal (ULN) (within 6 months of entry).
Pregnancy, planning pregnancy, or breastfeeding.
Patients who have been treated with thiopurines (mercaptopurine (PURINETHOL®), azathioprine (IMURAN®), or thioguanine) in the past 12 months or currently being treated with thiopurines are not eligible for the study. Usage of the thiopurines (azathioprine and mercaptopurine) with allopurinol has been shown to cause a significant drug-drug interaction.
Unlikely to survive 2 years because of comorbidities.
Currently taking \> 200 mg of allopurinol per day or any dose of febuxostat. Patients taking 200 mg or less of allopurinol daily may participate, provided they meet the eligibility criteria for flares and current SU, and they have not had a dose escalation in their allopurinol in the previous 6 months.
Patients with known allergic or hypersensitive reactions to allopurinol and not willing to initiate febuxostat if urate lowering is indicated.
Subjects that test positive for HLA-B\*5801 allele, a genetic marker for severe cutaneous adverse reactions caused by allopurinol and are unwilling to initiate febuxostat if urate lowering is indicated by the study. Subjects of higher risk, including Black/African American, Asian (except Japanese), native Hawaiian, or Pacific Islander descent will be tested at screening.

Exclusion Criteria

Candidates who meet any of the following criteria will be excluded from the study:
Diagnosis of CKD Stage 3B or worse (eGFR \< 45 mL/min/ 1.73 m2) at screening
More than one subcutaneous tophus on clinical examination at screening
Two or more episodes of renal colic in the past 5 years
Unable to provide informed consent.
AST/ALT \> 3 Ă— upper limit of normal (ULN) (within 6 months of entry).
Pregnancy, planning pregnancy, or breastfeeding.
Patients who have been treated with thiopurines (mercaptopurine (PURINETHOL®), azathioprine (IMURAN®), or thioguanine) in the past 12 months or currently being treated with thiopurines are not eligible for the study. Usage of the thiopurines (azathioprine and mercaptopurine) with allopurinol has been shown to cause a significant drug-drug interaction.
Unlikely to survive 2 years because of comorbidities.
Currently taking \> 200 mg of allopurinol per day or any dose of febuxostat. Patients taking 200 mg or less of allopurinol daily may participate, provided they meet the eligibility criteria for flares and current SU, and they have not had a dose escalation in their allopurinol in the previous 6 months.
Patients with known allergic or hypersensitive reactions to allopurinol and not willing to initiate febuxostat if urate lowering is indicated.
Subjects that test positive for HLA-B\*5801 allele, a genetic marker for severe cutaneous adverse reactions caused by allopurinol and are unwilling to initiate febuxostat if urate lowering is indicated by the study. Subjects of higher risk, including Black/African American, Asian (except Japanese), native Hawaiian, or Pacific Islander descent will be tested at screening.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Morgantown?

Yes, this clinical trial (NCT04875702) has an active research site in Morgantown, WV that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Gout Treatment Options in Morgantown, WV

If you're searching for gout treatment options in Morgantown, WV, this clinical trial (NCT04875702) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Morgantown research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced gout specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all gout clinical trials near you to find additional studies recruiting in your area.

More Gout Trials in Morgantown, WV

See all gout clinical trials recruiting in Morgantown — not just this study.

Browse Gout Trials in Morgantown →

Browse More Trials by Condition

Gout TrialsAll Conditions →

Ready to Join in Morgantown?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Morgantown, WV